| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Wright JD, Matsuo K, Huang Y, et al. Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines[J]. Obstet Gynecol, 2019, 134(1): 49-57.
|
| [3] |
Duenas-Gonzalez A. Combinational therapies for the treatment of advanced cervical cancer[J]. Expert Opin Pharmacother, 2023, 24(1): 73-81.
|
| [4] |
Bi Y, Wang Y, Zhang J, et al. Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer[J]. Abdom Radiol (NY), 2021, 46(12): 5715-5722.
|
| [5] |
Hu Y, Han Y, Shen Y, et al. Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial[J]. BMC Cancer, 2022, 22(1): 1270.
|
| [6] |
Kokka F, Bryant A, Brockbank E, et al. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer[J]. Cochrane Database Syst Rev, 2022, 8(8): Cd010260.
|
| [7] |
Raphael MJ, Karanicolas PJ. Regional therapy for colorectal cancer liver metastases: which modality and when?[J]. J Clin Oncol, 2022, 40(24): 2806-2817.
|
| [8] |
Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence[J]. Cancer Treat Rev, 2019, 72: 28-36.
|
| [9] |
Lu E, Shao G, Ma J, et al. Optimized Loading of Idarubicin in CalliSpheres(®) drug-eluting beads and characterization of release profiles and morphological properties[J]. Pharmaceutics, 2021, 13(6): 799.
|